DE60028754D1 - Feste dispersion mit ritonavir, fenofibrat oder griseofulvin - Google Patents

Feste dispersion mit ritonavir, fenofibrat oder griseofulvin

Info

Publication number
DE60028754D1
DE60028754D1 DE60028754T DE60028754T DE60028754D1 DE 60028754 D1 DE60028754 D1 DE 60028754D1 DE 60028754 T DE60028754 T DE 60028754T DE 60028754 T DE60028754 T DE 60028754T DE 60028754 D1 DE60028754 D1 DE 60028754D1
Authority
DE
Germany
Prior art keywords
solid dispersion
griseofulvin
fenofibrate
ritonavir
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60028754T
Other languages
English (en)
Other versions
DE60028754T2 (de
Inventor
K Krill
J Fort
Devalina Law
A Schmitt
Yihong Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of DE60028754D1 publication Critical patent/DE60028754D1/de
Publication of DE60028754T2 publication Critical patent/DE60028754T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60028754T 1999-11-12 2000-11-10 Feste dispersion mit ritonavir, fenofibrat oder griseofulvin Expired - Lifetime DE60028754T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43899499A 1999-11-12 1999-11-12
US438994 1999-11-12
PCT/US2000/031072 WO2001034119A2 (en) 1999-11-12 2000-11-10 Inhibitors of crystallization in a solid dispersion

Publications (2)

Publication Number Publication Date
DE60028754D1 true DE60028754D1 (de) 2006-07-27
DE60028754T2 DE60028754T2 (de) 2007-05-31

Family

ID=23742853

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60028754T Expired - Lifetime DE60028754T2 (de) 1999-11-12 2000-11-10 Feste dispersion mit ritonavir, fenofibrat oder griseofulvin

Country Status (7)

Country Link
US (1) US9107830B2 (de)
EP (1) EP1175205B1 (de)
JP (3) JP5767429B2 (de)
AT (1) ATE329579T1 (de)
CA (1) CA2359945C (de)
DE (1) DE60028754T2 (de)
WO (1) WO2001034119A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) * 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
KR20100090726A (ko) * 2002-02-26 2010-08-16 아스트라제네카 아베 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
SI21223A (sl) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
CN1318019C (zh) * 2002-07-04 2007-05-30 詹森药业有限公司 包含两种不同聚合物骨架的固体分散体
EP1829541A1 (de) * 2002-12-17 2007-09-05 Abbott GmbH & Co. KG Formulierung mit Fenofibrinsäure oder einem physiologisch verträglichen Salz davon
AU2013201423B2 (en) * 2003-08-28 2015-11-05 Abbvie Inc. Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
KR20060085682A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트 및 스타틴을 함유하는 고형 제제
JP5069001B2 (ja) 2003-10-10 2012-11-07 ベロクシス ファーマシューティカルズ エー／エス フィブラートを含む固体投与形態
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
CN1905860A (zh) * 2003-11-21 2007-01-31 先灵公司 磷酸二酯酶v抑制剂制剂
WO2005063209A1 (en) * 2003-12-23 2005-07-14 Tibotec Pharmaceuticals Ltd. Self-microemulsifying drug delivery systems of a hiv protease inhibitor
WO2005065657A2 (en) 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
US7576216B2 (en) 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
GB0502790D0 (en) * 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
AU2012202831B2 (en) * 2005-02-23 2015-01-22 Abbvie Inc. A solid pharmaceutical dosage formulation
AU2005330266A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or PEG/poloxamer
CA2600407A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Fibrate compositions containing a surfactant mixture of peg-600 and poloxamer 407
ATE549016T1 (de) * 2005-04-11 2012-03-15 Abbott Lab Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
CA2627351C (en) 2005-10-26 2012-05-01 Banner Pharmacaps, Inc. Lipophilic vehicle-based dual controlled release matrix system
US8333989B2 (en) 2005-10-26 2012-12-18 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
NZ593757A (en) * 2008-12-10 2013-03-28 Cipla Ltd Rifaximin complexes
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
CN103260609B (zh) 2010-12-23 2017-08-11 雅培股份有限两合公司 基于固体分散体的固体延缓制剂
US10286056B2 (en) * 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
JP5977062B2 (ja) * 2011-03-30 2016-08-24 興和株式会社 カフェイン含有液状組成物及び該組成物を充填したカプセル剤
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
EP3024442B1 (de) * 2013-07-22 2019-01-16 Sandoz AG Zusammensetzungen mit amorphem dapagliflozin
EP3027171B1 (de) * 2013-07-30 2020-03-25 Gilead Connecticut, Inc. Formulierung aus syk-hemmern
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
JP6235924B2 (ja) * 2014-02-13 2017-11-22 壽製薬株式会社 フェノフィブラートの固体分散体
WO2018227179A1 (en) * 2017-06-09 2018-12-13 Isp Investments Llc Small-molecule lactams in coamorphous pharmaceutical phases
JP6506810B2 (ja) * 2017-10-03 2019-04-24 壽製薬株式会社 フェノフィブラートの固体分散体
EA202191372A1 (ru) * 2018-12-14 2021-09-16 Фуджифилм Корпорэйшн Таблетка и способ получения таблетки
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS5649314A (en) * 1979-07-05 1981-05-02 Yamanouchi Pharmaceut Co Ltd Lasting pharmaceutical composition having prolonged action and its preparation
JPS56110612A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
US4769235A (en) 1984-01-27 1988-09-06 New York University Immunodominant epitope of the circumsporozoite surface protein
JPS61205208A (ja) * 1985-03-08 1986-09-11 Yamanouchi Pharmaceut Co Ltd 難溶性医薬品の速溶性製剤
US4590065A (en) 1985-04-18 1986-05-20 Colgate-Palmolive Company Stable flavor-containing dentifrice
JPS61205208U (de) 1985-06-12 1986-12-24
US4758427A (en) 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
PH22025A (en) 1985-08-19 1988-05-13 Johnson & Son Inc S C Aqueous pyrethroid insecticidal formulations and method of increasing the stability thereof
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3682208D1 (de) 1986-12-18 1991-11-28 Kurt Heinz Bauer Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
DE3839825A1 (de) * 1988-11-25 1990-06-13 Henning Berlin Gmbh Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze
GB8903328D0 (en) 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
HU204529B (en) 1989-08-10 1992-01-28 Richter Gedeon Vegyeszet Process for producing new 1-oxa-2-oxo-8-aza-spiro(4,5)decane derivatives and pharmaceutical compositions containing them
EP0489898A4 (en) 1990-06-01 1993-06-09 Research Corporation Technologies, Inc. Self-emulsifying glasses
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
EP0580860B2 (de) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Verfahren zur herstellung einer festen dispersion
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
DE4201179A1 (de) 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
DE69331930T2 (de) 1992-02-18 2003-01-09 Pharmos Corp Trockene zusammensetzungen zur herstellung von emulsionen im submikron-bereich
CA2095776C (en) 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
IT1256026B (it) 1992-06-12 1995-11-20 Sali del glutatione etilestere
DE4220782A1 (de) 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
DE4226753A1 (de) 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
WO1995022319A1 (en) 1994-02-16 1995-08-24 Abbott Laboratories Process for preparing fine particle pharmaceutical formulations
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
DE4446470A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von teilbaren Tabletten
DE4446468A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von umhüllten Tabletten
DE4446467A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von linsenförmigen Tabletten durch Schmelzkalandrierung
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19509806A1 (de) 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
DE19509805A1 (de) 1995-03-21 1996-09-26 Basf Ag Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
DE19531277A1 (de) 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
DE19536394A1 (de) 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
DE19602206A1 (de) 1996-01-23 1997-07-24 Basf Ag Zubereitungen nichtsteroidaler Analgetika
DE19617716A1 (de) 1996-05-03 1997-11-06 Basf Ag In wäßriger Lösung redispergierbare Polymerpulver
NZ330739A (en) 1996-05-20 1999-06-29 Janssen Pharmaceutica Nv Particulate solid dispersion of itraconazole and a water soluble polymer
CA2255663C (en) 1996-05-24 2002-08-20 Schering Corporation Antifungal composition with enhanced bioavailability
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
AU3146997A (en) 1996-06-03 1998-01-05 Merck & Co., Inc. Pediatric formulation for hiv protease inhibitors
DE19624607A1 (de) 1996-06-20 1998-01-02 Basf Ag Verfahren zur Herstellung von Salzen von Säuregruppen tragenden pharmazeutischen Wirkstoffen
DE19635676A1 (de) 1996-09-03 1998-03-05 Basf Ag Feste geschäumte Wirkstoffzubereitungen
TW474824B (en) 1996-09-13 2002-02-01 Basf Ag The production of solid pharmaceutical forms
US5727878A (en) 1996-10-17 1998-03-17 Cdf Corporation Liner for a mixing container and an assembly and method for mixing fluid components
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
FR2756736B1 (fr) 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6197787B1 (en) 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
DE19709663A1 (de) 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten als Bindemittel zur Herstellung von festen pharmazeutischen Darreichungsformen
DE19710009A1 (de) 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
DE19710213A1 (de) 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
US5948426A (en) 1997-05-03 1999-09-07 Jefferies; Steven R. Method and article to induce hematopoietic expansion
DE19721467A1 (de) 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
JPH1125076A (ja) 1997-06-30 1999-01-29 Fujitsu Ltd 文書管理装置および文書管理プログラム記憶媒体
US5955475A (en) 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
EP0896823B1 (de) 1997-07-15 2002-09-25 Development Center For Biotechnology Verbesserte Stabilisierung von Misoprostol
DE19733505A1 (de) 1997-08-01 1999-02-04 Knoll Ag Schnell wirksames Analgeticum
AU9496798A (en) 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
CA2310847C (en) 1997-11-28 2007-03-13 Knoll Aktiengesellschaft Method for producing solvent-free non-crystalline biologically active substances
US6632455B2 (en) * 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
JPH11271927A (ja) * 1998-01-20 1999-10-08 Mitsubishi Paper Mills Ltd 画像材料用支持体
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
DE19814730A1 (de) 1998-04-02 1999-10-07 Basf Ag Verwendung von N-Vinyllacram oder N-Vinylamin haltigen Copolymeren als Matrix zur Herstellung von festen pharmazeutischen und kosmetischen Darreichungsformen
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
DE19839276A1 (de) 1998-08-28 2000-03-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19840256A1 (de) 1998-09-03 2000-03-09 Basf Ag Verfahren zur Herstellung von beschichteten festen Dosierungsformen
DE19841244A1 (de) 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
DE19842914A1 (de) 1998-09-18 2000-03-23 Basf Ag Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
DE19847618A1 (de) 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6502135B1 (en) 1998-10-30 2002-12-31 Science Applications International Corporation Agile network protocol for secure communications with assured system availability
DE19853985A1 (de) 1998-11-23 2000-05-25 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19855440A1 (de) 1998-12-01 2000-06-08 Basf Ag Verfahren zum Herstellen fester Darreichungsformen mittels Schmelzextrusion
DE19856147A1 (de) 1998-12-04 2000-06-08 Knoll Ag Teilbare feste Dosierungsformen und Verfahren zu ihrer Herstellung
DE19901383A1 (de) 1999-01-15 2000-07-20 Knoll Ag Verfahren zur Herstellung unterschiedlicher fester Dosierungsformen
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
FR2793689B1 (fr) 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
SI1183026T1 (sl) 1999-06-04 2006-10-31 Abbott Lab Izboljsane farmacevtske spojine, vsebujoce ritonavir
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19930454A1 (de) 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
EA005423B1 (ru) 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
US7364752B1 (en) * 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE60017444T2 (de) 1999-11-12 2006-02-09 Abbott Laboratories, Abbott Park Pharmazeutische formulierungen auf basis fester dispersionen
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
DE19960494A1 (de) 1999-12-15 2001-06-21 Knoll Ag Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
EP2269591B1 (de) 2000-01-19 2018-04-04 AbbVie Inc. Verbesserte pharmazeutische zusammensetzungen
DE10013289A1 (de) 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
DE10026699A1 (de) 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
AU2001279284A1 (en) 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
DE10038571A1 (de) 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
WO2002020057A2 (en) 2000-09-05 2002-03-14 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
DE10046541A1 (de) 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
JP4101661B2 (ja) 2001-05-03 2008-06-18 エフ．ホフマン−ラ ロシュ アーゲー 非晶質メシル酸ネルフィナビルの製薬剤形
CN100549007C (zh) 2001-05-11 2009-10-14 泰博特克药品有限公司 广谱2-氨基-苯并唑磺酰胺hiv蛋白酶抑制剂
MXPA03010771A (es) 2001-05-25 2004-07-01 Abbott Lab Capsulas elasticas blandas que comprenden ritonavir y/o lopinavir.
WO2002096392A1 (en) 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
MXPA03011933A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados.
AU2002304387A1 (en) 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
EP1269994A3 (de) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
CA2452330C (en) 2001-07-06 2011-03-22 Lifecycle Pharma A/S Controlled agglomeration
US20040195187A1 (en) 2001-07-09 2004-10-07 Jeroen Groenenboom Inhibiting scale deposition in oilfield tubulars
DE10133570C1 (de) 2001-07-13 2002-09-05 Octel Corp Verfahren zur Reinigung von Wasser
JP2003068576A (ja) * 2001-08-30 2003-03-07 Rohm Co Ltd 面実装型固体電解コンデンサの構造及びその製造方法
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2474838C (en) 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
DE10213242A1 (de) 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
AU2003243699B2 (en) 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
AR039744A1 (es) 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
CN100515388C (zh) 2002-06-26 2009-07-22 金拓 难溶药物快速溶出固体剂型
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
DE60329188D1 (de) 2002-08-12 2009-10-22 Bend Res Inc Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
ATE487470T1 (de) 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
DE10247037A1 (de) 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
ATE359777T1 (de) 2002-12-17 2007-05-15 Abbott Gmbh & Co Kg Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040258752A1 (en) 2003-01-31 2004-12-23 Paruthi Manoj Kumar Taste masking pharmaceutical composition and process for its preparation
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
US7862834B2 (en) 2003-05-28 2011-01-04 Novartis Pharma Ag Pharmaceutical formulation comprising a water-insoluble active agent
KR100767271B1 (ko) 2003-07-11 2007-10-17 에프. 호프만-라 로슈 아게 사퀴나비르 메실레이트 경구 투여 형태
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
PL1748762T3 (pl) 2004-05-28 2014-05-30 Abbvie Deutschland Postać dawkowania, dająca się otrzymać ze sproszkowanej mieszaniny zawierającej nieorganiczny pigment
WO2007111866A2 (en) 2006-03-23 2007-10-04 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto

Also Published As

Publication number Publication date
ATE329579T1 (de) 2006-07-15
JP6122087B2 (ja) 2017-04-26
WO2001034119A9 (en) 2002-09-26
US20070249692A1 (en) 2007-10-25
WO2001034119A2 (en) 2001-05-17
DE60028754T2 (de) 2007-05-31
US9107830B2 (en) 2015-08-18
EP1175205B1 (de) 2006-06-14
JP2013224297A (ja) 2013-10-31
CA2359945C (en) 2011-04-26
JP2003513904A (ja) 2003-04-15
JP2016065073A (ja) 2016-04-28
EP1175205A2 (de) 2002-01-30
JP5767429B2 (ja) 2015-08-19
JP5873043B2 (ja) 2016-03-01
CA2359945A1 (en) 2001-05-17
WO2001034119A3 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
ATE329579T1 (de) Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
MY169471A (en) Controlled release preparation
BG103425A (en) Pharmaceutical composition
CA2322315A1 (en) Fast disintegrating tablets
YU38802A (sh) Nova kompozicija i njena upotreba
AR024384A1 (es) UNA FORMA DE DOSIFICACIoN FARMACÉUTICA DE DISOLUCIoN INSTANTÁNEA Y UN MÉTODO PARA PREPARARLA
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
WO2000040205A3 (en) Sustained release formulation with reduced moisture sensitivity
HK1068282A1 (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease
WO1998038983A3 (en) Swallow tablet comprising paracetamol
DK1227797T3 (da) Farmaceutiske faststofdispersionsformuleringer
KR850001693A (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
WO2003000203A3 (en) Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
MY136059A (en) Swallow tablet comprising paracetamol
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
GEP20033078B (en) Controlled-Release Compositions of Betahistine
ATE296606T1 (de) Schnell freisetzende farmazeutische darreichungsform enthaltend polymorphes tibolon
ES2313578T3 (es) Formulacion estable que comprende una combinacion de un farmaco sensible a la humedad y un segundo farmaco y procedimiento de preparacion de la misma.
ATE300293T1 (de) Pharmazeutische zusammensetzungen, die schwerlösliche arzneistoffe enthalten
WO2004096155A3 (en) Tablets and methods for modified release of hydrophilic and other active agents
GB0006897D0 (en) Medicaments
ECSP982436A (es) Composicion
MY116032A (en) Liquid composition comprising an hiv protease inhibitor and a, c12-c18 fatty acid

Legal Events

Date Code Title Description
8364 No opposition during term of opposition